CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Polyamine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03094546
NCT03094546Phase 2Completed
CompareCT.gov

Effect of Polyamine-enriched Dietary Supplementation on Cognitive Function and Biomarkers in Elderly Individuals With Subjective Cognitive Decline

Charite University, Berlin, Germany·interventional·Posted Mar 29, 2017·Updated Apr 26, 2021

In Brief

A Phase 2 clinical trial evaluating Polyamine and Placebo for Subjective Cognitive Decline (SCD). Completed, enrolled 100 participants across 1 site.

Detailed Summary

The overall objective of this study is to examine the effect of polyamine supplementation on cognitive performance and further characterization of individuals with subjective cognitive decline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubjective Cognitive Decline (SCD)
CountriesGermany
CollaboratorsFreie Universität Berlin, Karl-Franzens-Universität, Institute of Molecular Biosciences, Graz, Austria

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 29, 2017
Enrollment StartJan 1, 2017
Primary CompletionMay 1, 2020
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.3 years ago

Interventions

Polyaminedietary

12 months of polyamine supplementation (6 capsules/day)

Placebodietary

12 months of placebo intake (6 capsules/day)